- cafead Jul 02, 2024 at 11:22: AM
via Boehringer Ingelheim and Gubra have initiated a Phase I clinical trial of BI 3034701, a long-acting triple agonist peptide designed to treat obesity.
The randomised, first-in-human, placebo-controlled trial will evaluate the drug’s tolerability, safety, and pharmacokinetics and be carried out in two parts.
article source
The randomised, first-in-human, placebo-controlled trial will evaluate the drug’s tolerability, safety, and pharmacokinetics and be carried out in two parts.
article source